We focused on AD risk among people with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, and related conditions, where TNF-a is implicated, and TNF-a inhibiting drugs are FDA approved for use. Here, TNF is linked to ulcerative colitis.